Phase 2b Controlled Trial of M72/AS01

Simple item page
dc.contributor.affiliationFrom GlaxoSmithKline, Wavre, Belgium (O.V.D.M., M.-A.D., T.S., E.J.A., A.K.A., A.B., P.G.); South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology (M.H., T.J.S., M.T.), and Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine (R.J.W., F.T.), University of Cape Town, Task Applied Science (E.V.B., A.D.), Stellenbosch University (A.D.), and Aeras Global TB Vaccine Foundation (D.R.T.) Cape Town, Setshaba Research Centre, Pretoria (M. Malahleha), the Aurum Institute, Klerksdorp and Tembisa Research Centres (J.C.I.), and the Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, South African Medical Research Council Collaborating Centre for HIV/AIDS and TB, and National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, University of the Witwatersrand (N.M.), Johannesburg, and Be Part Yoluntu Centre, Paarl (E.H.) - all in South Africa; Kenya Medical Research Institute, Nairobi (V.N.); Francis Crick Institute (R.J.W.), the Department of Medicine, Imperial College London (R.J.W.), and the London School of Hygiene and Tropical Medicine (H.M.A.) - all in London; Centre for Infectious Disease Research in Zambia (M. Muyoyeta, G.H.) and Zambart, University of Zambia (H.M.A.) - both in Lusaka, Zambia; the Department of Internal Medicine, University Hospital of Zurich, Zurich, Switzerland (F.T.); and Aeras, Rockville (G.L.B., A.M.G., T.G.E.), and Johns Hopkins University Center for Tuberculosis Research, Baltimore (N.M.) - both in Maryland.
dc.contributor.affiliationCIDRZ
dc.contributor.affiliationCentre for Infectious Disease Research in Zambia (CIDRZ)
dc.contributor.authorVan Der Meeren O
dc.contributor.authorHatherill M
dc.contributor.authorNduba V
dc.contributor.authorWilkinson RJ
dc.contributor.authorMuyoyeta M
dc.contributor.authorVan Brakel E
dc.contributor.authorAyles HM
dc.contributor.authorHenostroza G
dc.contributor.authorThienemann F
dc.contributor.authorScriba TJ
dc.contributor.authorDiacon A
dc.contributor.authorBlatner GL
dc.contributor.authorDemoitié MA
dc.contributor.authorTameris M
dc.contributor.authorMalahleha M
dc.contributor.authorInnes JC
dc.contributor.authorHellström E
dc.contributor.authorMartinson N
dc.contributor.authorSingh T
dc.contributor.authorAkite EJ
dc.contributor.authorKhatoon Azam A
dc.contributor.authorBollaerts A
dc.contributor.authorGinsberg AM
dc.contributor.authorEvans TG
dc.contributor.authorGillard P
dc.contributor.authorTait DR
dc.date.accessioned2025-05-23T11:41:28Z
dc.date.issued2018-Oct-25
dc.description.abstractBACKGROUND: A vaccine to interrupt the transmission of tuberculosis is needed. METHODS: We conducted a randomized, double-blind, placebo-controlled, phase 2b trial of the M72/AS01 RESULTS: We report the primary analysis (conducted after a mean of 2.3 years of follow-up) of the ongoing trial. A total of 1786 participants received M72/AS01 CONCLUSIONS: M72/AS01
dc.identifier.doi10.1056/NEJMoa1803484
dc.identifier.urihttps://pubs.cidrz.org/handle/123456789/10488
dc.sourceThe New England journal of medicine
dc.titlePhase 2b Controlled Trial of M72/AS01

Files

Collections

Published